PMID- 17159795
OWN - NLM
STAT- MEDLINE
DCOM- 20070607
LR  - 20191210
IS  - 0172-780X (Print)
IS  - 0172-780X (Linking)
VI  - 27 Suppl 2
DP  - 2006 Dec
TI  - Simultaneous determination of amphetamines and amphetamine-derived designer drugs 
      in human urine by GC-MS.
PG  - 121-4
AB  - OBJECTIVES: The purpose of this study is to evaluate the gas chromatographicmass 
      spectrometric method (GC-MS) for assay of stimulants of amphetamine type: 
      amphetamine (AMP), methamphetamine (MAMP), ephedrine (EPH), norephedrine 
      (NOREPH), and the amphetamine-derived designer drugs 
      3,4-methylenedioxyamphetamine (MDA), 3,4-methylenedioxymethamphetamine (MDMA, 
      ecstasy), 3,4-methylenedioxy-N-ethylamphetamine (MDEA) and 
      N-methyl-benzodioxolylbutanamine (MBDB) in urine. These drugs are often 
      encountered in forensic and clinical toxicological analysis. METHODS: GC-MS 
      method after mixed-mode solid-phase extraction (SPE) and derivatization with 
      heptafluorobutyric anhydride (HFBA) is presented for quick and reliable screening 
      as well as identification and quantification of amphetamines and amphetamine 
      derived designer drugs in urine. RESULTS: The measurement of calibration 
      dependence allowed to determine the extent of linearity in the concentration 
      range from 10 to 2,000 ng/ml for all amphetamines except AMP and for all 
      amphetamine-derived designer drugs with correlation coefficients exceeding 0.98. 
      Detection limits were established at 5 ng/ml and quantification limits at 10 
      ng/ml for all analytes, except AMP. LOD for AMP was established at 20 ng/ml and 
      LOQ at 50 ng/ml. Extraction efficiency for all analytes at concentration levels 
      50 and 500 ng/ml (n=6) was established in the range 60-99%. Repeatability was 
      measured at concentration levels 50 and 500 ng/ml (n=6), relative standard 
      deviations (RSDs) were under 10% for all analytes. CONCLUSIONS: The GC-MS method 
      after mix-mode solid-phase extraction and derivatization with heptafluorobutyric 
      anhydride is presented for screening followed by identification and 
      quantification of AMP, MAMP, EPH, NOREPH, MDA, MDMA, MDEA, and MBDB. The 
      applicability of the GC-MS method was proven by analyzing authentic urine 
      samples.
FAU - Maresova, Vera
AU  - Maresova V
AD  - Institute of Forensic Medicine and Toxicology, Charles University, 1st Medical 
      School, Prague, Czech Republic. vera.maresova@lf1.cuni.cz
FAU - Chadt, Jiri
AU  - Chadt J
FAU - Prikryl, Lukas
AU  - Prikryl L
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Sweden
TA  - Neuro Endocrinol Lett
JT  - Neuro endocrinology letters
JID - 8008373
RN  - 0 (Amphetamines)
RN  - 0 (Designer Drugs)
SB  - IM
MH  - Amphetamines/*urine
MH  - Designer Drugs/*analysis
MH  - Gas Chromatography-Mass Spectrometry/*methods
MH  - Humans
MH  - Reproducibility of Results
MH  - Sensitivity and Specificity
MH  - Substance Abuse Detection/*methods
EDAT- 2006/12/13 09:00
MHDA- 2007/06/08 09:00
CRDT- 2006/12/13 09:00
PHST- 2006/09/15 00:00 [received]
PHST- 2006/10/25 00:00 [accepted]
PHST- 2006/12/13 09:00 [pubmed]
PHST- 2007/06/08 09:00 [medline]
PHST- 2006/12/13 09:00 [entrez]
AID - NEL270806A27 [pii]
PST - ppublish
SO  - Neuro Endocrinol Lett. 2006 Dec;27 Suppl 2:121-4.